320 related articles for article (PubMed ID: 31718595)
41. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
42. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
Chen Y; Li Y; Gao H
Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
[TBL] [Abstract][Full Text] [Related]
43. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
44. Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression.
Cai X; Zhao Z; Dong J; Lv Q; Yun B; Liu J; Shen Y; Kang J; Li J
Cell Death Dis; 2019 Feb; 10(3):184. PubMed ID: 30796202
[TBL] [Abstract][Full Text] [Related]
45. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
46. LncRNA RGMB-AS1 is activated by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma.
Zhang Z; Li SY; Zhang LB
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1979-1986. PubMed ID: 29687852
[TBL] [Abstract][Full Text] [Related]
47. Single-cell and bulk RNA sequencing reveal heterogeneity and diagnostic markers in papillary thyroid carcinoma lymph-node metastasis.
Lu DN; Zhang WC; Lin YZ; Jiang HY; He R; Li SL; Zhang YN; Shao CY; Zheng CM; Xu JJ; Ge MH
J Endocrinol Invest; 2024 Jun; 47(6):1513-1530. PubMed ID: 38146045
[TBL] [Abstract][Full Text] [Related]
48. Circ_PSD3 promotes the progression of papillary thyroid carcinoma via the miR-637/HEMGN axis.
Li Z; Huang X; Liu A; Xu J; Lai J; Guan H; Ma J
Life Sci; 2021 Jan; 264():118622. PubMed ID: 33203523
[TBL] [Abstract][Full Text] [Related]
49. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
50. AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour.
Wei M; Wang Y; Liu Y; Li D; He X
World J Surg Oncol; 2022 Oct; 20(1):334. PubMed ID: 36203174
[TBL] [Abstract][Full Text] [Related]
51. Upregulation of microRNA-143-3p induces apoptosis and suppresses proliferation, invasion, and migration of papillary thyroid carcinoma cells by targeting MSI2.
Wang ZL; Wang C; Liu W; Ai ZL
Exp Mol Pathol; 2020 Feb; 112():104342. PubMed ID: 31738908
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract][Full Text] [Related]
53. Thyroid papillary carcinoma combined with primary follicular lymphoma: a case report.
Xu T; Wu L; Ye H; Luo S; Wang J
Diagn Pathol; 2024 May; 19(1):69. PubMed ID: 38773600
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression.
Zhang R; Yu Y; Yang Y; Zhang M; Zhang X; Chang Y; Wang S; Hu L; Li J; Zheng X; Zhao R; Guo Y; Ni X
Med Oncol; 2024 May; 41(6):160. PubMed ID: 38763968
[TBL] [Abstract][Full Text] [Related]
55. MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28.
Zhang Y; Li F; Chen J
Oncol Rep; 2019 Apr; 41(4):2511-2517. PubMed ID: 30720110
[TBL] [Abstract][Full Text] [Related]
56. [Effects of UHRF1 on Estrogen Receptor and Proliferation, Invasion and Migration of BCPAP Cells in Thyroid Papillary Carcinoma].
Xu LW; Zhang LY; Gou X; Qiu YB; Liu ZM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):325-330. PubMed ID: 32543137
[TBL] [Abstract][Full Text] [Related]
57. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
[TBL] [Abstract][Full Text] [Related]
58. Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation.
Xie R; Chen W; Lv Y; Xu D; Huang D; Zhou T; Zhang S; Xiong C; Yu J
J Formos Med Assoc; 2023 Aug; 122(8):738-746. PubMed ID: 36739231
[TBL] [Abstract][Full Text] [Related]
59. High expression of LINC0163 promotes progression of papillary thyroid cancer by regulating epithelial-mesenchymal transition MITF.
Gao P; Jiao H; Zhe L; Cui J
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5504-5511. PubMed ID: 32495885
[TBL] [Abstract][Full Text] [Related]
60. Down-regulated
Zeng J; Ma X; Wang J; Liu R; Shao Y; Hou Y; Li Z; Fang Y
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31101684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
